Misplaced Pages

Edward Tobinick

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.

This is an old revision of this page, as edited by Tom.Bot (talk | contribs) at 21:38, 14 December 2020 (Task 6: +{{Authority control}}, WP:GenFixes on). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Revision as of 21:38, 14 December 2020 by Tom.Bot (talk | contribs) (Task 6: +{{Authority control}}, WP:GenFixes on)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff)
Edward Tobinick
BornNew York City, US
NationalityAmerican
Alma materBrandeis University (B.S. Biology, 1973)
UC San Diego School of Medicine (M.D., 1977)
OccupationPhysician
Known forPerispinal Etanercept
Websitehttp://www.nrimed.com

Edward Tobinick M.D. is an American physician, inventor, and scientist, who invented the use of the drug etanercept for chronic neurological dysfunction after stroke and brain injury, with multiple issued U.S. and foreign patents, including U.S. patent 8,900,583.

On October 6, 2018, Greg Hunt MP, the Minister for Health (Australia), announced that his government was allocating funds specifically for the study of perispinal etanercept for the rehabilitation of stroke survivors in Australia.

Selected publications

Year Article Journal / Textbook
2010 Edward Tobinick, Perispinal Etanercept: A New Therapeutic Paradigm in Neurology.   Expert Review of Neurotherapeutics 2010 Jun;10(6):985-1002.
2011 Edward Tobinick, Rapid improvement of chronic stroke deficits after perispinal etanercept: three consecutive cases.   CNS Drugs 2011, 25(2): p. 145-55.
2012 Tobinick, E., N.M. Kim, G. Reyzin, H. Rodriguez-Romanacce, and V. DePuy, Selective TNF inhibition for chronic stroke and traumatic brain injury: an observational study involving 629 consecutive patients treated with perispinal etanercept.   CNS Drugs 2012, 26(12): p. 1051–70.
2014 Ignatowski, T.A., R.N. Spengler, K.M. Dhandapani, H. Folkersma, R.F. Butterworth, and E. Tobinick, Perispinal etanercept for post-stroke neurological and cognitive dysfunction: scientific rationale and current evidence.   CNS Drugs 2014, 25(2): p. 145-55.
2014 Tobinick, E., H. Rodriguez-Romanacce, A. Levine, T.A. Ignatowski, and R.N. Spengler, Immediate neurological recovery following perispinal etanercept years after brain injury.   Clin Drug Investig 2014, 34(5): p. 361-6.
2016 Edward Tobinick, Perispinal Delivery of CNS Drugs.   CNS Drugs 2016 Jun;30(6):469-80.
2017 Tobinick, E., H. Rodriguez-Romanacce, R. Kinssies, and N.M. Kim, Chapter 7 - Perispinal Etanercept for Traumatic Brain Injury.   New Therapeutics for Traumatic Brain Injury, K.A. Heidenreich, Editor. 2017, Academic Press/Elsevier: New York.
2018 Edward Tobinick, Perispinal etanercept advances as a neurotherapeutic.   Expert Review of Neurotherapeutics 2018, 18(6): p. 453-455.

References

  1. Singh, Anita (February 7, 2017). "Andrew Marr: how having a stroke changed my marriage for the better". The Telegraph. Retrieved November 17, 2018.
  2. "New hope for survivors of stroke and traumatic brain injury". Springer Select. October 31, 2012. Retrieved November 17, 2018.
  3. "Stroke drug trial set for Australia". SBS News. October 6, 2018. Retrieved November 17, 2018.
  4. Hunt MP, Greg (October 6, 2018). "$1 million to support the rehabilitation of stroke survivors". Australia Ministry of Health. Retrieved November 17, 2018.

Selected patents

Year Issued Inventor Title Country
2009 Edward Tobinick Methods to facilitate transmission of large molecules across the blood-brain, blood-eye, and blood-nerve barriers. U.S. Patent 7,629,311”   US
2014 Edward Tobinick Methods for treatment of brain injury using biologics. U.S. Patent 8,900,583   US
Categories: